Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iRITUX: AI-based Personalized Rituximab Protocol in Membranous Nephropathy
2024-510718-34-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in membranous glomerulonephritis (MGN) comparing AI-personalized rituximab dosing (iRITUX algorithm) with Standard-of-care rituximab regimen (2 arms). Planned start Sep 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2024-510718-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510718-34-00.